Xifaxan vs Generic Rifaximin: Are They Really the Same?

If your doctor has prescribed rifaximin for SIBO and you've taken it to the pharmacy, you may have experienced a moment of sticker shock: Xifaxan, the brand-name rifaximin product from Salix Pharmaceuticals, carries a list price exceeding $2,000 for a standard 14-day course of 550 mg three times daily. For patients without insurance coverage — and many SIBO patients fall into this category, since rifaximin is often prescribed off-label for SIBO rather than for its FDA-approved IBS-D indication — this price is simply prohibitive. The obvious question becomes: is there a generic version? Can I get rifaximin from another country? What about compounded rifaximin? And does any of this actually work as well as brand-name Xifaxan? These are practical, important questions, and the answers are more nuanced in 2026 than they were even a few years ago.

Why Xifaxan Costs So Much: The Patent Story

Rifaximin itself is not a new molecule — it was originally developed by the Italian company Alfa Wassermann in the 1980s and has been used in Europe for decades. Salix Pharmaceuticals licensed the compound for the US market and conducted the large clinical trials required for FDA approval, eventually receiving approval for travelers' diarrhea in 2004, hepatic encephalopathy in 2010, and IBS-D in 2015. The development and trial costs, combined with the US pharmaceutical patent system, gave Salix substantial pricing power. Salix's strategy for extending market exclusivity has been controversial and legally contested. The company holds patents not just on rifaximin itself (which as an older molecule has limited patent life) but on a specific crystalline form of the drug called the alpha polymorph — a particular physical structure of the rifaximin crystal that Salix claims provides distinct absorption and stability characteristics. Generic manufacturers, including Amneal Pharmaceuticals and others, have challenged these patents through patent litigation under the Hatch-Waxman Act, arguing that the alpha polymorph patents are not sufficiently distinct to justify continued exclusivity. Salix has successfully defended some of these challenges through 2024 and 2025, delaying widespread generic entry into the US market. The legal battles over rifaximin patents are among the most closely watched in pharmaceutical intellectual property, with several cases working through the federal court system.

Generic Rifaximin Availability in 2026

As of 2026, the US generic rifaximin market remains limited but has made more progress than in prior years. Amneal Pharmaceuticals received FDA approval for a generic rifaximin 550 mg tablet in 2022 for the hepatic encephalopathy indication and has been navigating ongoing patent litigation for the IBS-D and broader SIBO-relevant indication. Several other generic manufacturers have ANDAs (abbreviated new drug applications) pending with the FDA for rifaximin across its approved indications. Whether a given pharmacy stocks the generic versus the brand, and at what cost, varies substantially by state, insurance formulary, and pharmacy chain. As of 2026, patients in some states and with certain insurance plans can access generic rifaximin at significantly reduced cost — sometimes $50-200 for a course compared to the $2,000+ brand price. Patients who have been told there is no generic should check directly with GoodRx, Mark Cuban's Cost Plus Drugs (which carries rifaximin at dramatically reduced prices), and pharmacy benefit managers about their specific plan's formulary. The situation is evolving rapidly and can change faster than any published article can track.

Cost Plus Drugs (costplusdrugs.com), founded by Mark Cuban, has become a significant resource for rifaximin access. As of 2024, Cost Plus Drugs listed rifaximin 550 mg tablets at approximately $50-60 per month — a transformative price point compared to the Xifaxan list price. Availability and pricing at Cost Plus can fluctuate based on supply, but this platform has provided a genuine access option for many SIBO patients who were previously priced out of rifaximin treatment. The Cost Plus rifaximin is manufactured by licensed generic pharmaceutical companies and meets FDA standards for bioequivalence.

Compounded Rifaximin: A Gray Area

Compounding pharmacies can prepare rifaximin in custom formulations — including different doses, liquid forms for patients who cannot swallow tablets, or combined preparations. Compounded rifaximin occupies a regulatory gray area: compounding pharmacies are permitted to prepare medications when there is a documented clinical need that the commercially available product cannot meet (such as a specific dose not available commercially, or an allergy to an inactive ingredient). However, compounded medications are not FDA-approved and do not undergo the same bioequivalence testing as generic pharmaceuticals. The consistency, purity, and actual rifaximin content of compounded preparations depend heavily on the quality of the compounding pharmacy and the raw rifaximin powder they source. For patients who genuinely cannot afford brand or generic rifaximin and are not appropriate candidates for herbal alternatives, compounded rifaximin from a reputable 503B outsourcing facility (which operates under stricter FDA oversight than standard compounding pharmacies) may be an option to discuss with their provider. Using compounded rifaximin from an unknown or unverified source is not recommended.

International Rifaximin: Mexico, India, and Beyond

Rifaximin has been available as a generic medication in many countries outside the United States for years. In Mexico, rifaximin is sold under various brand names (including Normix, the original Alfa Wassermann brand) and as generics, at a fraction of the US price. Mexican pharmacies in border cities like Tijuana and Nuevo Laredo are accessible to US residents in border states, and some patients travel specifically to purchase rifaximin. In India, rifaximin generics are manufactured by major pharmaceutical companies including Cipla and Sun Pharma and are available at very low cost. Patients who purchase medications from international sources must understand that they are operating outside FDA oversight, and the quality assurance processes of foreign manufacturers vary. Indian generic manufacturers who supply to regulated markets (US, EU) undergo FDA inspection and meet international quality standards; those who supply only to domestic markets may not. The legal status of importing medications for personal use from abroad is a gray area under FDA policy — the FDA has discretion to allow importation of a personal supply for personal use when no safety threat is apparent, but this policy can be applied inconsistently. Consulting with your prescribing physician before pursuing international rifaximin sources is strongly advisable.

Are Generics and Brand Equivalent for SIBO?

FDA-approved generic medications must demonstrate bioequivalence to the brand-name product — meaning the generic delivers a statistically equivalent amount of active drug to the bloodstream over time (area under the curve within 80-125% of the reference product). For a minimally absorbed drug like rifaximin, where the primary therapeutic effect occurs in the GI lumen rather than via systemic absorption, bioequivalence testing is more complex. The FDA has required rifaximin generics to demonstrate local GI activity equivalence, not just plasma concentration equivalence. FDA-approved generic rifaximin products that have cleared these requirements should be considered therapeutically equivalent to Xifaxan for clinical purposes, including SIBO treatment. The alpha polymorph argument — that Xifaxan's specific crystal form makes it clinically superior — has not been validated in head-to-head clinical outcome trials comparing the brand to approved generics. In the absence of such evidence, there is no compelling clinical reason to insist on the brand product if an FDA-approved generic is available at lower cost. The significant proviso is 'FDA-approved': non-FDA-approved products (whether compounded, imported, or from unregulated sources) do not carry the same assurance of equivalence.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.